Posts tagged ‘Hematology New Products’
Understanding the biology of Chronic Lymphocytic Leukemia (CLL) & indolent B-cell lymphoma
April 15th, 2011
Daedalus
In order to understand the mechanism of action (MOA) of a drug, you first have to know the underlying biology of the disease. This is particularly important for new products, where you are often analyzing how you compare to competitors, and the strengths and weaknesses each may have in their MOA.
In anticipation of new data at the forthcoming American Society of Clinical Oncology (ASCO) meeting, Sally Church on Pharma Strategy Blog provides a review of two hematologic malignancies, indolent B-cell lymphoma and chronic lymphocytic leukemia (CLL).
In Sally’s post, she applies what we know about the underlying science to current drug therapies. One of her conclusions is that FCR (fludarabine, cyclophosphamide, rituximab) “is now very much the bedrock of treatment for patients with CLL and is based on a very solid rationale.”
For those interested in what new therapies are emerging for CLL, you’ll have to read further on Pharma Strategy Blog.
Sally is a regular attendee at the annual meetings of the American Society of Hematology (ASH) and ASCO, and has particular expertise in this area. Please feel free to contact us to find out how we can help you bring new hematology products to market.
It is a sad day for Japan and its people. Any natural disaster does provide graphic testimony of the fragility of life and the lack of predictability of what may happen to any of us.
Today, Icarus Consultant’s hematology expert, Dr Sally Church in a poignant post on Pharma Strategy Blog provides some perspective on what is happening in Japan and whether we will see an increase in leukemia as a result.
She discusses the higher incidence of leukemia and lymphoma that has been seen in children living around the Sellafield nuclear fuel reprocessing plant in Cumbria, in the North West of England.
Only long-term epidemiology studies will show the true consequences of any radiation exposure, so it may be many years before we can measure the true impact of what has happened in Japan.